A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML
Mosialou I, Ali A, Cuesta-Dominguez A, Labella R, Vgenopoulou V, Bisikirska B, Galan-Diez M, Wang A, Bewersdorf J, Liang C, Heiblig M, Jurcic J, Berman E, Rabadan R, Kornblau S, Garcia-Manero G, Raza A, Kousteni S. A Niche Driven Mechanism Determines Response to ATRA and a Mutation-Independent Therapeutic Approach for MDS and AML. Blood 2024, 144: 5788-5788. DOI: 10.1182/blood-2024-212307.Peer-Reviewed Original ResearchAcute myeloid leukemiaAcute myeloid leukemia patientsStandard of careComplete responseMyelodysplastic syndrome patientsMyelodysplastic syndromeOverall response rateResponse to ATRAAll-trans-retinoic acidB-cateninOsteoblast lineage cellsMyeloid malignanciesTreatment responseLineage cellsDuration of follow-upMonitoring of treatment responseResponse rateBone marrow biopsyAbsolute neutrophil countAdverse risk groupAcute myeloid leukemia cellsNotch signalingAssociated with complete inhibitionResponse to all-trans-retinoic acidResistance to standard